News articles about Alnylam Pharmaceuticals (NASDAQ:ALNY) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.9451761883996 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment’s analysis:
- Alnylam Pharma (ALNY) Announces New Clinical Results from the APOLLO Phase 3 Study of Patisiran (streetinsider.com)
- Alnylam and Ionis in the red on positive late-stage data on Pfizer’s amyloidosis drug tafamidis (seekingalpha.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) COO Yvonne Greenstreet Sells 7,221 Shares (americanbankingnews.com)
- Dicerna Pharma Has Multiple Pipeline Opportunities, Tough Competition, Analyst Says In Neutral Initiation (msn.com)
- Alnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL) (finance.yahoo.com)
Shares of NASDAQ:ALNY opened at $119.10 on Friday. The firm has a market cap of $13,009.26, a price-to-earnings ratio of -22.01 and a beta of 2.67. Alnylam Pharmaceuticals has a 12-month low of $46.90 and a 12-month high of $153.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.23 and a quick ratio of 12.23.
Several analysts have recently weighed in on ALNY shares. Credit Suisse Group set a $151.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, February 9th. Jefferies Group set a $156.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. B. Riley reissued a “buy” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, December 11th. Chardan Capital reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Friday, January 19th. Finally, Piper Jaffray reissued a “buy” rating and issued a $182.00 target price on shares of Alnylam Pharmaceuticals in a report on Sunday, January 7th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Alnylam Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $134.15.
In other news, President Barry E. Greene sold 38,460 shares of the business’s stock in a transaction dated Wednesday, March 14th. The shares were sold at an average price of $143.10, for a total transaction of $5,503,626.00. Following the transaction, the president now owns 97,544 shares in the company, valued at approximately $13,958,546.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Akshay Vaishnaw sold 88,554 shares of the business’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $143.10, for a total transaction of $12,672,077.40. Following the transaction, the insider now owns 55,856 shares in the company, valued at approximately $7,992,993.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,365 shares of company stock valued at $33,239,418. 4.30% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This news story was first reported by BBNS and is owned by of BBNS. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/03/30/alnylam-pharmaceuticals-alny-given-daily-media-impact-score-of-0-22/1974598.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.